Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.46 |
| ▸ | MAP1LC3A | Q9H492 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543716 | 1.00 | CA12 (0.52) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| Acetic Acid SCHEMBL29692693 | 0.98 | CA12 (0.50) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL990344 | 0.89 | KDM4E (0.57) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL14725053 | 0.89 | CA12 (0.64) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL29947213 | 0.89 | CA12 (0.64) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL29758957 | 0.89 | CA12 (0.64) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL4757393 | 0.88 | MAP1LC3B (0.42) | CA12CA1CA9MAP1LC3BMAP1LC3A | |
| SCHEMBL3258147 | 0.86 | CA12 (0.56) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL11442830 | 0.86 | CA12 (0.56) | CA12CA1CA9KDM4EALDH1A1 | |
| SCHEMBL29544308 | 0.86 | CA12 (0.56) | CA12CA1CA9KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3656861-B1 | ACTIVE MMP9-BINDING PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| CN-112423779-B | Peptides for the treatment of retinitis pigmentosa | 第一三共株式会社 | 2025-04-11 | — | — | CN | disclosed |
| US-20240360200-A1 | KLK5 INHIBITORY PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-10-31 | — | — | US | disclosed |
| US-20240294610-A1 | PEPTIDE FOR TREATING AGE-RELATED MACULAR DEGENERATION | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-05 | — | — | US | disclosed |
| US-20240270803-A1 | PEPTIDE FOR TREATING RETINITIS PIGMENTOSA | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-15 | — | — | US | disclosed |
| CN-110234760-B | Peptides for the treatment of age-related macular degeneration | 第一三共株式会社 | 2024-08-06 | — | — | CN | disclosed |
| US-12043658-B2 | Conjugate comprising an active MMP-9-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-23 | — | — | US | disclosed |
| US-12024547-B2 | KLK5 inhibitory peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| US-11926655-B2 | Active MMP9-binding peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-03-12 | — | — | US | disclosed |
| US-11866472-B2 | Peptide for treating retinitis pigmentosa | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-01-09 | — | — | US | disclosed |
| WO-2011006938-A1 | USE OF PROANTHOCYANIDINS FOR PRODUCTION OF AN ANTIADHESIVE PREPARATION | Westfälische Wilhelms Universität Münster (DE) | 2011-01-20 | — | — | WO | disclosed |
| WO-2009040534-A1 | DIAGNOSTIC METHOD | THE SECRETARY OF STATE FOR ENVIRONMENT, FOOD & RURAL AFFAIRS (DEFRA) (GB) | 2009-04-02 | — | — | WO | disclosed |
| EP-0802909-B1 | SUBSTITUTED OXAZOLIDINE CALPAIN AND/OR CATHEPSIN B INHIBITORS | AVENTIS PHARMA INC (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-0791071-B1 | ASSAY FOR PROLINE IMINOPEPTIDASE AND OTHER HYDROLYTIC ACTIVITIES | LITMUS CONCEPTS INC (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5691368-A | THERAPY FOR NEURODEGENERATIVE DISORDERS | HOECHST MARION ROUSSEL, INC. (US) | 1997-11-25 | — | — | US | disclosed |
| EP-0802909-A2 | SUBSTITUTED OXAZOLIDINE CALPAIN AND/OR CATHEPSIN B INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0791071-A1 | ASSAY FOR PROLINE IMINOPEPTIDASE AND OTHER HYDROLYTIC ACTIVITIES | LITMUS CONCEPTS, INC. (US) | 1997-08-27 | — | — | EP | disclosed |
| US-5571684-A | SOLID PHASE CONJUGATE | LITMUS CONCEPTS, INC. (US) | 1996-11-05 | — | — | US | disclosed |
| WO-1996021655-A2 | SUBSTITUTED OXAZOLIDINE CALPAIN AND/OR CATHEPSIN B INHIBITORS | HOECHST MARION ROUSSEL, INC. (US) | 1996-07-18 | — | — | WO | disclosed |
| WO-1996015255-A2 | ASSAY FOR PROLINE IMINOPEPTIDASE AND OTHER HYDROLYTIC ACTIVITIES | LITMUS CONCEPTS, INC. (US) | 1996-05-23 | — | — | WO | disclosed |